Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single arm phase II trial of the combination of
bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC
progressive after first or second-line therapy. The main objective is to evaluate the
progression-free survival in patients with advanced or metastatic non-squamous NSCLC being
treated with ixabepilone and bevacizumab.